Ipilimumab和Nivolumab在抗pd -1治疗进展后黑色素瘤脑转移中的颅内预后

IF 20.1 1区医学 Q1 ONCOLOGY

JAMA Oncology Pub Date : 2025-01-30 DOI:10.1001/jamaoncol.2024.6168

Sarah E. Lochrin, Hannah L. Kalvin, James W. Smithy, Monica F. Chen, Parisa Momtaz, Alexander N. Shoushtari, Katherine S. Panageas, Michael A. Postow

引用次数: 0

摘要

这项队列研究探讨了ipilimumab-nivolumab治疗进展性黑色素瘤脑转移患者在抗程序性细胞死亡1 （anti-PD-1）治疗后的反应和生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy

This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1 (anti–PD-1) therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JAMA Oncology Medicine-Oncology

自引率

1.80%

发文量

423

期刊介绍： JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.